



OMELYANOVSKIY VITALY VLADIMIROVICH

Born on July 27, 1964 in the city of Obninsk, Russian Federation

In 1987 he graduated from Pirogov Russian National Research Medical University with a specialization in “General Medicine” and obtained the qualification of “General Practitioner”. On graduating from the higher educational institution, he remained there for eight years, working his way up from Research Technician to Professor of the Chair of Clinical Pharmacology. In 1998 he graduated from the Russian Presidential Academy of National Economy and Public Administration with a specialization in “State and Municipal Management” and obtained the qualification of “Financial Economist”.

In 2002 he defended his first doctoral thesis in the Russian Federation on clinical and economic analysis and pharmacoeconomics.

From 1995 to 2005 he held the position of Deputy Head of the Medical Education Department and then the position of Head of the Department of Government Institution Affairs and Pharmacoeconomics in the representative office of GlaxoSmithKline plc (Great Britain) in Moscow.

From 2005 to 2009 he was Head of the Branch of the International Medical Devices Manufacturers Association in the Russian Federation.

From 1998 to 2000 he was Head of the Clinical Pharmacology Department of Moscow City Clinical Hospital No. 13.

From 2009 to 2012 he was Director of the Research Institution of Clinical and Economic Expert Analysis and Pharmacoeconomics of Pirogov Russian National Research Medical University.

From 2012 he has been Chief of the Research Laboratory of Technology and Healthcare Assessment of the Institute of Applied Economic Research of the Russian Presidential Academy of National Economy and Public Administration.

From 2014 he has been Head of the Center for Healthcare Funding of the Research Financial Institute of the Ministry of Finance of Russia.

From 2015 he has been General Director of Federal State Budgetary Institution, the Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation.

He is Head of the Healthcare Expert Board of the Council of the Federation Committee on Social Policy and Expert of the Analytical Center for the Government of the Russian Federation.

He is Chief Clinical Pharmacologist of the Ministry of Health of Moscow Oblast.

Doctor Med. Sci. (2002), Professor (2007)

He has certificates of merit of the President of the Russian Federation and the Chairman of the Federation Council of the Federal Assembly of the Russian Federation and testimonials of the Chairman of the Federation Council of the Federal Assembly of the Russian Federation, Analytical

Center for the Government of the Russian Federation, Russian Presidential Academy of National Economy and Public Administration, Government of Sverdlovsk Oblast.

He is the author of three patents of the Russian Federation, two monographs, guidance manuals for physicians and more than 140 research papers published in national and foreign medical publications. He is Editor-in-Chief of the following academic journals: “Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology” and “Medical Technologies. Assessment and Selection”.

One doctoral and seven Ph.D. theses have been defended under the supervision of V.V. Omelyanovskiy. He is currently supervising theses of two post-graduate students and two postdoctoral students.

Over the last several years, health technology assessment (HTA) has been increasingly utilized to provide input into a national decision-making process in Russia. Since 2014, it has become compulsory to conduct HTA for pharmaceutical products in order to be included in the reimbursement lists. The Center for Healthcare Quality Assessment and Control is a recognized federal HTA agency is entrusted with promotion of transparency and standardization, including working with expert groups to assess their knowledge, educating stakeholders in the use of HTA, and developing methodologies and decision-making criteria. Moreover, HTA is emerging in CIS countries while Russia has taken part in the promotion of HTA initiatives for the decision-making in these counties. At this point of building HTA system, can favorably impact the HTA environment in Russia and other CIS counties on the grounds of experience sharing and expert leadership of countries with developed HTA systems. I share common aspiration to contribute to HTA communities and believe that the membership in HTAi Board of Directors promises good perspectives for the future mutual development.